Emergency management of adrenal insufficiency in children: advocating for treatment options in outpatient and field settings


ABSTRACT
Adrenal insufficiency (AI) remains a significant cause of morbidity and mortality in children with 1 in 200 episodes of adrenal crisis resulting in death. The goal of this working group of the Pediatric Endocrine Society Drug and Therapeutics Committee was to raise awareness on the importance of early recognition of AI, to advocate for the availability of hydrocortisone sodium succinate (HSS) on emergency medical service (EMS) ambulances or allow EMS personnel to administer patient’s HSS home supply to avoid delay in administration of lifesaving stress dosing, and to provide guidance on the emergency management of children in adrenal crisis. Currently, hydrocortisone, or an equivalent synthetic glucocorticoid, is not available on most ambulances for emergency stress dose administration by EMS personnel to a child in adrenal crisis. At the same time, many States have regulations preventing the use of patient’s home HSS supply to be used to treat acute adrenal crisis. In children with known AI, parents and care providers must be made familiar with the administration of maintenance and stress dose glucocorticoid therapy to prevent adrenal crises. Patients with known AI and their families should be provided an Adrenal Insufficiency Action Plan, including stress hydrocortisone dose (both oral and intramuscular/intravenous) to be provided immediately to EMS providers and triage personnel in urgent care and emergency departments. Advocacy efforts to increase the availability of stress dose HSS during EMS transport care and add HSS to weight-based dosing tapes are highly encouraged.

INTRODUCTION
Prismatic clinical scenario
A 9-year-old boy presented to a local emergency department (ED) with chronic abdominal pain, acute onset of nausea and vomiting for the previous 24 hours. Physical examination revealed an ill-appearing, thin male with tachycardia (pulse 110 bpm), mild hypotension (85/60 mm Hg), signs of dehydration, and hyperpigmentation. Laboratory testing showed hyponatremia (sodium 129 mEq/L), hyperkalemia (potassium 5.8 mEq/L) and hypoglycemia (glucose 55 mg/dL). Despite urgent fluid resuscitation with 2 intravenous boluses of normal saline and a bolus of 10% dextrose, hypotension persisted. Due to clinical and biochemical features suggestive of primary adrenal insufficiency (AI), blood was drawn for measurement of adrenocorticotropic hormone (ACTH) and cortisol levels prior to administering 75 mg of intravenous hydrocortisone sodium succinate (Solucor). He was admitted and diagnosis confirmed. Treatment was initiated with hydrocortisone and fludrocortisone. The patient and family received education for the management of primary AI and prevention of adrenal crises.

Two years later he developed acute gastroenteritis with fever, vomiting and diarrhea while visiting his grandparents in a rural area. He received triple his usual dose of oral hydrocortisone, but vomited within 10 minutes. Grandparents had hydrocortisone sodium succinate available for intramuscular injection, but did not know how to administer it and called 911. The patient was unresponsive on arrival of the ambulance 20 minutes later. Grandparents informed the emergency medical technicians (EMT) that he needs to receive hydrocortisone sodium succinate intramuscularly for AI. Due to emergency medical services (EMS) policy, the EMTs were not allowed to administer the child’s personal supply of hydrocortisone sodium succinate and did not have an alternative medication on the ambulance. Glucometer revealed a blood glucose of 30 mg/dL. While EMTs attempted to place an intravenous catheter, he experienced a seizure. He was intubated and received intravenous dextrose with cessation of the seizure. He was transported to a local ED that was 30 minutes away. In the ED, he was given 75 mg intravenous hydrocortisone sodium succinate and was admitted to the intensive care unit where he later died of complications related to prolonged hypoglycemia and aspiration pneumonia.

BACKGROUND
Adrenal crisis is a life-threatening condition that can be prevented by recognition in which patients with AI must receive additional
glucocorticoids when under physiological stress. Adrenal crisis can also occur as the initial clinical presentation of AI. Appropriate management requires immediate recognition of the clinical signs, symptoms and biochemical profile of AI and the triggers for adrenal crisis. Therefore, primary care, urgent care and ED providers must be trained to recognize the diverse clinical circumstances in which AI can occur. In children with known AI, parents and care providers must be familiar with the administration of maintenance and stress doses glucocorticoid therapy to prevent adrenal crises. This can be facilitated by providing the family with a written Adrenal Insufficiency Action Plan and Emergency Care Letter. Currently, hydrocortisone, or an equivalent synthetic glucocorticoid, is not available on most ambulances for emergency administration by EMS personnel. In addition, EMT training on the use of patient’s home medication is not widely employed. Both of these situations can lead to life-threatening delays in providing appropriate therapy to prevent or treat adrenal crises.

AI is a significant cause of morbidity and mortality in children, with an annual estimated incidence of adrenal crisis of 5–10 episodes per 100 patient-years, with increasing rates in some countries. One in every 200 episodes of adrenal crisis results in death. Therefore, the goal of this working group was to raise awareness on the importance of early recognition and provide guidance on the emergency management of AI in children during illnesses, particularly in the outpatient, EMS and ED settings.

### ETIOLOGY
AI is characterized by impaired adrenal synthesis of glucocorticoids. When reduced production of mineralocorticoid (aldosterone) is present it is associated with hyponatremia due to salt-wasting and reciprocal hyperkalemia. AI can be categorized as primary, where the defect is in the adrenal gland, or secondary (central), where the defect is due to hypothalamic and/or pituitary dysfunction. In the central forms deficient secretion of ACTH leads to atrophy of the zona fasciculata in the adrenal cortex (the source of glucocorticoids); mineralocorticoid production by the zona glomerulosa is preserved because the renin-angiotensin system is intact.

The most common cause of primary AI in children is congenital adrenal hyperplasia (CAH), the leading cause of atypical genitalia in female newborns. Less common causes of primary AI include autoimmune adrenalitis (isolated or part of autoimmune polyglandular syndromes), infections, bilateral adrenal hemorrhage, and various genetic

---

**Table 1** Congenital causes of adrenal insufficiency

<table>
<thead>
<tr>
<th>Condition</th>
<th>Affected gene</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary CAH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21-ox-hydroxylase deficiency CYP21A2</td>
<td>46,XX DSD/androgen excess; salt-wasting</td>
<td></td>
</tr>
<tr>
<td>3β-hydroxysteroid dehydrogenase deficiency HSD3B2</td>
<td>Ambiguous genitalia/salt-wasting</td>
<td></td>
</tr>
<tr>
<td>11β-hydroxylase deficiency CYP11B2</td>
<td>46,XX DSD/androgen excess; hypertension (not infants)</td>
<td></td>
</tr>
<tr>
<td>P450 side-chain cleavage syndrome CYP11A</td>
<td>46,XY DSD; salt-wasting; hypogonadism</td>
<td></td>
</tr>
<tr>
<td>Lipoid hyperplasia StAR</td>
<td>46,XY DSD; salt-wasting; hypogonadism</td>
<td></td>
</tr>
<tr>
<td>P450 oxidoreductase deficiency (PORD) POR</td>
<td>46,XY DSD, salt-wasting, hypogonadism, Antley-Bixler malformation; altered drug metabolism</td>
<td></td>
</tr>
<tr>
<td>Congenital adrenal hypoplasia SF-1 (NRS1A)</td>
<td>46,XY DSD, gonadal insufficiency</td>
<td></td>
</tr>
<tr>
<td>DAX-1 (NROB1)</td>
<td>Hypogonadotropic hypogonadism</td>
<td></td>
</tr>
<tr>
<td>CDKN1C</td>
<td>IMAGe syndrome (intrauterine growth retardation, metaphyseal dysplasia, genital anomalies)</td>
<td></td>
</tr>
<tr>
<td>Triple A or Allgrove AAS</td>
<td>Achalasia, alacrima</td>
<td></td>
</tr>
<tr>
<td>Isolated familial glucocorticoid deficiency (FGD) MC2R, MRAp</td>
<td>Tall stature, normal mineralocorticoid production</td>
<td></td>
</tr>
<tr>
<td>FGD–DNA repair defect MCM4</td>
<td>NK-cell defect, short stature, recurrent viral infections, microcephaly, chromosomal breakage</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid resistance GCCR</td>
<td>Mineralocorticoid/androgen excess</td>
<td></td>
</tr>
<tr>
<td>Metabolic diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenoleukodystrophy ABCD1</td>
<td>Neurologic deterioration</td>
<td></td>
</tr>
<tr>
<td>Zellweger PEX</td>
<td>Cerebrohepatoportal syndrome</td>
<td></td>
</tr>
<tr>
<td>Smith-Lemli-Opitz DHCR7</td>
<td>46,XY sex reversal, polyactyly, mental retardation</td>
<td></td>
</tr>
<tr>
<td>Wolman LIAP</td>
<td>Hepatomegaly</td>
<td></td>
</tr>
<tr>
<td>Mitochondrial disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kearns-Sayre</td>
<td>Ophthalmoplegia, myopathy</td>
<td></td>
</tr>
<tr>
<td>Secondary: hypothalamus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holoprosencephaly GIU2, FGFI8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRH deficiency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal hypercortisolemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary: pituitary/hypothalamus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolated ACTH deficiency TPTI</td>
<td>Septo-optic dysplasia (optic nerve hypoplasia), nystagmus</td>
<td></td>
</tr>
<tr>
<td>Multiple anterior pituitary hormone deficiencies due to pituitary aplasia/hypoplasia HESX1</td>
<td>X linked, mental retardation, ectopic posterior pituitary</td>
<td></td>
</tr>
<tr>
<td>Proopiomelanocortin deficiency POMC</td>
<td>Severe early-onset hyperphagic obesity, red hair</td>
<td></td>
</tr>
<tr>
<td>Proprotein convertase 1 mutation PCSX1</td>
<td>Hypoglycemia, malabsorption, gonadotropin deficiency</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1 Continued**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Affected gene</th>
<th>Clinical phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proprotein convertase 1 mutation PCSX1</td>
<td>Severe early-onset hyperphagic obesity, red hair</td>
<td></td>
</tr>
<tr>
<td>Proopiomelanocortin deficiency POMC</td>
<td>Hypoglycemia, malabsorption, gonadotropin deficiency</td>
<td></td>
</tr>
<tr>
<td>ACTH, adrenocorticotropic hormone; CAH, congenital adrenal hyperplasia; CRH, corticotropin-releasing hormone; DSD, disorder of sex development; NK, natural killer.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
hematopoietic and solid organ transplants. Glucocorticoids administered by intra-articular, topical, intradermal, and inhaled routes may also suppress the hypothalamic-pituitary-adrenal (HPA) axis. Other medications, such as megestrol acetate, ketoconazole, and mifepristone, also impair adrenal function via direct and indirect mechanisms. Less common secondary causes of ACTH deficiency involving the pituitary and hypothalamus include tumors, radiation exposure, congenital anomalies, and specific gene defects (table 1 and box 1). Inherited forms of ACTH deficiency are usually associated with additional pituitary hormone deficiencies.

The magnitude of suppression of the HPA axis in relation to dose, duration, and type of glucocorticoid therapy can vary among individuals due to variability in glucocorticoid pharmacokinetics and interindividual glucocorticoid receptor sensitivity. Generally, the HPA axis recovers rapidly when the duration of glucocorticoid treatment is short, that is, less than 7–10 days, even when high doses are used. In these circumstances, it is appropriate to discontinue glucocorticoid therapy. However, if the duration of therapy is 3 weeks or longer, it is recommended that the glucocorticoid dose be tapered gradually to avoid precipitating symptoms of steroid dependence and/or AI. Protracted use of supraphysiological glucocorticoid doses may result in severe adrenal gland atrophy and prolonged AI lasting up to 34 weeks requiring glucocorticoid tapering to be extended over many months.

A Cochrane review of 8 studies of 9218 children with acute lymphoblastic leukemia treated with prolonged courses of supraphysiological doses of long-acting glucocorticoids, including dexamethasone, prednisolone and prednisone, revealed that AI occurred in nearly all children in the first days after discontinuation of glucocorticoids. However, the precise duration of glucocorticoid therapy and tapering protocol were not reported in the majority of the studies. While most of the children recovered within several weeks, a few children had prolonged AI lasting up to 34 weeks. Fluconazole was noted in one of these studies to possibly prolong the duration of AI while another study identified stress and infection to be risk factors.

A meta-analysis examining the role of intra-articular corticosteroids (ICS) in suppression of the HPA axis noted no AI with ICH doses of \( \leq 400 \) mcg of beclomethasone dipropionate daily. However, subsequent reports have noted HPA axis suppression at lower ICS doses. Since the bioavailability and bioequivalence of ICS preparations vary along with individual glucocorticoid sensitivity, it is difficult to identify a threshold dose for all ICS that will cause HPA axis suppression. Therefore, it is important to recognize chronic ICS therapy as a risk factor for AI. A study of infants with hemangiomas treated with high-dose glucocorticoid therapy for 12–26 weeks demonstrated the return of normal circadian response in salivary cortisol levels within 6 weeks and normal response to administration of low-dose ACTH stimulation by 12 weeks after stopping treatment.

During the process of recovery from HPA suppression, physiological circadian secretion of cortisol may recover before return of the ability of the hypothalamus to respond to stress. Therefore, a patient may have a normal 8:00 AM cortisol, but still be unable to show an appropriate serum cortisol response to stress. The wide variability in

### Box 1 Acquired causes of adrenal insufficiency

**Primary**
- Autoimmune adrenalitis (Addison disease)
  - Isolated.
  - Autoimmune polyendocrinopathy type 1.
  - Autoimmune polyendocrinopathy type 2.
- Bilateral hemmorhage/infarction
  - Trauma.
  - Waterhouse-Friderichsen syndrome.
  - Anticoagulation.
- Drug effect: mifepristone, aminoglutethimide, mitotane, ketoconazole, etomidate, metyrapone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, suninib).
- Infection
  - Viral: HIV, cytomegalovirus.
  - Fungal: coccidioidomycosis, histoplasmosis, blastomycosis, cryptococcosis.
  - Mycobacterial: tuberculosis.
- Amoebic.
- Infiltrative
  - Hemochromatosis, histiocytosis, sarcoidosis, amyloidosis, neoplasm.
- Surgery: bilateral adrenalectomy

**Secondary:**
- Pituitary
- Corticosteroid withdrawal after prolonged administration (inhaled, intranasal, oral, rectal, intravenous and topical).
- Corticosteroid withdrawal after parenteral administration of high doses of potent and longer acting preparations (intramuscular, intradermal and intra-articular routes).
- Drug effect: megestrol, mitotane, medroxyprogesterone, rifampin, phenytoin, barbiturates, tyrosine kinase inhibitors (eg, suninib).
- Inflammatory disorders.
- Trauma.
- Radiation therapy.
- Surgery.
- Tumors: craniopharyngioma, germinoma.
- Infiltrative disease: sarcoidosis, histiocytosis.

**Secondary:**
- Pituitary
- Corticosteroid withdrawal after prolonged administration.
- Trauma.
- Tumor: craniopharyngioma.
- Radiation therapy.
- Lymphocytic hypophysitis.

The most common cause of secondary (central) AI is low ACTH due to iatrogenic suppression of the pituitary corticotrophs by prolonged use of supraphysiological doses of oral glucocorticoids typically prescribed for the treatment of medical conditions including but not limited to asthma, hematologic/oncologic conditions, inflammatory bowel disorders, rheumatologic conditions, nephrotic syndrome, neurologic disorders, postneurosurgical procedures, and syndromes including X linked adrenoleukodystrophy (see table 1 and box 1).
Diagnosis of Acute AI
Diagnosis of AI can be challenging as the clinical signs are not specific and may progress insidiously over time. Adrenal crisis can be precipitated by acute illness, physical stress or injury requiring increased cortisol production above basal needs in the setting of normal adrenal function. In addition, induction of anesthesia and surgery can precipitate acute AI.

Clinical signs
Acute AI can present with fatigue, weakness, tachycardia, hypotension, dizziness, nausea, vomiting, abdominal pain, diaphoresis and seizures. If unrecognized and not treated quickly, AI can progress to coma and death. Prolonged cholestatic jaundice, failure to gain weight and hypoglycemia may be the presenting clinical features in neonates and infants. Micropenis, bilateral cryptorchidism and, rarely, central diabetes insipidus may also be present in neonates who have AI due to panhypopituitarism. Individuals with primary AI may have hyperpigmentation of the skin (particularly creases, folds and scars), gums and buccal mucosa.

General biochemistry
In acute AI, hyponatremia is the most consistent biochemical finding. Hyperkalemia is present in primary, but not secondary AI, and can be associated with hypercalcemia and metabolic acidosis. Hypoglycemia is more frequent in neonates and infants regardless of the type of AI. Other findings include normocytic anemia, lymphocytosis and eosinophilia.

Hormonal measurements and provocative testing
The diagnosis of primary AI is suggested by blood tests preferably performed at 8:00 AM that show an ACTH level greater than 100 pg/mL and a cortisol level less than 10 mcg/dL or by an ACTH level that is twofold greater than the upper limit of the normal range and a cortisol level less than 5 mcg/dL. Low serum aldosterone with elevated plasma renin activity is the hallmark of mineralocorticoid deficiency. Secondary AI is associated with low levels of both cortisol and ACTH. An 8:00 AM serum cortisol level of ≤3 mcg/dL is highly suggestive of the diagnosis whereas a cortisol value of ≥18 mcg/dL essentially excludes AI. If AI is suspected during an acute illness, a random cortisol and ACTH should be obtained prior to initiating glucocorticoid therapy. A serum cortisol concentration less than 18 mcg/dL during acute illness can be indicative of AI. Cortisol and ACTH levels may be difficult to interpret in neonates and infants as circadian pattern of secretion does not appear until 4 months and cortisol-binding globulin is not detectable in infants until 4 months27 and cortisol-binding globulin is low causing low total, but not free, serum cortisol.

If levels of plasma ACTH and/or serum cortisol are equivocal, dynamic testing of adrenal function with cosyntropin should be done. Typically a high-dose cosyntropin stimulation test is preferred when primary AI is suspected (usual dose is 15 mcg/kg in neonates, 125 mcg in infants <2 years, and 250 mcg in older children). In secondary AI, dynamic testing with either high or low-dose cosyntropin (1 mcg) has been used for evaluation of the HPA axis. Regardless of the cosyntropin dose used, a serum cortisol level >18 mcg/dL rules out AI. The low-dose protocol is not universally accepted primarily due to technical factors influencing the test results. A dose of 1 mcg cosyntropin requires preparation by the person carrying out the test. Also, the prepared dilution should be given intravenously without using a catheter made of ‘fluorinated ethylene propylene’ plastic to which the cosyntropin binds.

Treatment
There is limited empirical evidence to guide the optimal glucocorticoid stress-dosing of children and adolescents who have AI. While the debate about what constitutes physiological stress is unresolved, several situations are generally accepted as significant stress including: fever >38°C (100.4°F), intercurrent illness with emesis, prolonged or voluminous diarrhea, infectious disease requiring antibiotics, acute trauma requiring medical intervention (eg, fracture) and anesthesia and associated surgical procedures. Guidelines on cortisol requirement in times of physiological stress have been based on the general acceptance that conditions of maximal stress increase the serum cortisol levels by 2–3 times. Treatment recommendations below are based on recent literature on glucocorticoid replacement therapy.

Outpatient Prevention of Acute AI
General pediatricians and endocrinologists
Following the diagnosis of AI, comprehensive educational outreach should include the family and caregivers, the primary care physician, and the local emergency care providers regarding the signs, symptoms and treatment of cortisol deficiency to prevent adrenal crises. Electronic medical records (EMR) may be used to flag patients with known or high risk for AI to increase provider attention.

The first step in preventing acute AI is maintenance glucocorticoid replacement therapy. Maintenance dosing of glucocorticoid is based on the secretory rate of cortisol which has been reported to be 5–8 mg/m²/d in healthy controls. For primary AI other than CAH, hydrocortisone at 8–12 mg/m²/d in 3 divided doses is recommended. In CAH, the consensus dosing is 10–15 mg/m²/d. Patients with secondary AI may be maintained on a lower dose. A challenge with hydrocortisone therapy is its short median elimination half-life, especially in children with CAH (58 minutes (range: 41–105 minutes)) allowing most of the hydrocortisone dose to be eliminated from the body within 4–7 hours. To prevent alternating periods of hypocortisolemia and hypercortisolemia throughout each day in children with AI, hydrocortisone should be administered in at least 3 divided doses. A 6-hour pharmacokinetic/pharmacodynamic study in children with CAH showed that maximum suppression of adrenal steroids (17-hydroxy-progesterone and androstenedione) occurs 3–4 hours after hydrocortisone dose and that adrenal steroids rebounded toward elevated baseline concentrations by the...
end of 6 hours.\textsuperscript{11} This suggests that the elimination half-life of cortisol is more relevant to adrenal steroid suppression than the biological or pharmacological half-life of cortisol (8 hours).\textsuperscript{39} Because of hydrocortisone pharmacokinetic properties and in order to mimic physiological circadian cortisol profiles, the highest hydrocortisone dose should be given in the morning.\textsuperscript{11, 31, 40}

Long-acting glucocorticoids such as dexamethasone, prednisone and prednisolone are not recommended for maintenance glucocorticoid therapy in growing children.\textsuperscript{26, 36, 41, 42} The use of long-acting glucocorticoids, such as dexamethasone, in treatment of initial adrenal crisis will prevent the provider from performing an ACTH stimulation test during the initial hospitalization to establish the definitive diagnosis. Prednisolone and dexamethasone are 15-fold and 80–100-fold more potent, respectively, than hydrocortisone in terms of growth suppression.\textsuperscript{42, 44} A modified-release formulation of hydrocortisone (Chronocort) given twice daily has been studied in adults with CAH\textsuperscript{44} but failed to meet the phase 3 trial primary objective confirming its superiority over conventional treatment.\textsuperscript{45}

During infancy to early childhood, smaller doses and incremental adjustments are required to avoid the adverse effects of glucocorticoid excess including obesity, hypertension, impaired growth, osteoporosis and insulin resistance. However, lack of availability of tablets in strengths lower than 5 mg makes dosing of infants difficult and less precise. Currently there is no commercially available liquid formulation that provides dosing in 0.1 mg increments since withdrawal of hydrocortisone cypionate suspension in 2001.\textsuperscript{46} Quatering 5 mg (6.5 mm) or 10 mg (8 mm) hydrocortisone tablets can lead to inconsistent cortisol levels and result in either undertreatment or overtreatment due to unacceptable dose variability.\textsuperscript{47, 48} Crushed, weighed hydrocortisone capsules from a compounding pharmacy may also lead to inconsistent cortisol levels and overtreatment.\textsuperscript{49, 50} Alcohol-free hydrocortisone oral suspension (2 mg/mL) prepared from 10 mg tablets provides good dose repeatability when shaken before use and was stable for 90 days when stored in either a bottle or syringe at either 4°C or 25°C.\textsuperscript{51} A pharmacokinetic study in children with CAH showed no difference in the extent or rate of hydrocortisone absorption between alcohol-free hydrocortisone suspension prepared from 10 mg tablets by a compounding pharmacy and hydrocortisone tablets.\textsuperscript{52} Future studies may encourage the development of a Food and Drug Administration (FDA)-approved commercially available alcohol-free hydrocortisone suspension. Uncoated minitablets of 2.5 mg (3 mm) could also be an alternative.\textsuperscript{48, 53–55} Multiparticulate hydrocortisone granules (Alkindi) with doses of 0.5, 1, 2 and 5 mg have been recently licensed in Europe.\textsuperscript{35}

In this guideline, we outline an Adrenal Insufficiency Action Plan (figure 2) and an Adrenal Insufficiency Instructions for Emergency Room Staff (figure 3), a stepwise approach to hydrocortisone dosing during illness similar to the extremely successful Asthma Action Plan.\textsuperscript{56} Our goal is to provide clear guidance for caregivers, primary care physicians, urgent care and emergency providers for appropriate stress dosing of hydrocortisone or its equivalent in children with known AI during illness and surgical procedures to prevent and treat adrenal crisis. The Adrenal Insufficiency Action Plan provides instructions for oral stress dosing with hydrocortisone (double or triple the daily dose given every 6–8 hours) and injectable hydrocortisone dosing when unable to take oral stress dose. All children with AI should be provided with an individualized care plan (Adrenal Insufficiency Action Plan and/or medical letter, see figures 1, 2 and 3), which could be made available in EMRs. The use of such tools has been shown to improve patient education regarding management of physiological stress in outpatient settings.\textsuperscript{52, 53} In addition, children with AI need a medical alert identification for EMS personnel.

All caregivers should be educated on the use of injectable intramuscular hydrocortisone sodium succinate in the event of emesis or an altered state of consciousness. As administration of intramuscular hydrocortisone sodium succinate requires multiple preinjection steps, a prefilled, single-use autoinjector (ZENEO Hydrocortisone) is in development in France. The use of rectal hydrocortisone suppositories in the management of adrenal crisis may not achieve desired cortisol concentrations.\textsuperscript{57}

**EMS and hospital transport treatment of acute AI**

Children with known AI requiring EMS transport should receive an intramuscular injection of potentially life-saving hydrocortisone sodium succinate as soon as possible by the family/caretaker or by EMS providers either using the family’s supply or having hydrocortisone sodium succinate available in the EMS vehicles, including mobile care units. Prolonged transportation times for patients living in rural areas may delay administration for several hours further underscoring the importance of EMS access to hydrocortisone sodium succinate. Clearly, local and state regulations and provider practice scope need to be considered by the agency’s medical director prior to implementation. In addition, we need to advocate that local and state regulations be updated to support the emergent administration of hydrocortisone sodium succinate by EMS personnel outside the hospital to individuals with known AI. A small number of states and provinces have legislation allowing administration of patient-carried medication and have EMS glucocorticoid protocols in place.\textsuperscript{58, 59} In this emergency setting, hydrocortisone sodium succinate should be administered at 50–100 mg/m\textsuperscript{2} intramuscularly (5–10 times the physiologic cortisol secretory rate).\textsuperscript{1, 3, 5, 26, 60} The Endocrine Society Clinical Practice Guideline suggests stress doses of hydrocortisone sodium succinate based on patient’s age: children ≤3 years: 25 mg; school-age children (≥3 and <12 years): 50 mg; and older children and adolescents (≥12 years): 100 mg as an initial stress dose.\textsuperscript{26, 61, 62} We recommend using the 100 mg/2 mL vial as its dilution is simple if smaller doses are needed. Finally, we also recommend adding age-related hydrocortisone sodium succinate dosing to weight-based dosing tapes used in emergency care of children, as their use is ubiquitous.\textsuperscript{63}

Regarding other glucocorticoids, dexamethasone sodium phosphate (1.5–2 mg/m\textsuperscript{2}/dose)\textsuperscript{5} has been available in some EMS settings and used in secondary AI. However, it is not suitable for treatment of salt-wasting adrenal crisis in primary AI because it has no mineralocorticoid effect. Methylprednisolone sodium succinate (10–25 mg/m\textsuperscript{2}/dose intramuscular) may be used to treat adrenal crisis although it has less mineralocorticoid activity than hydrocortisone.\textsuperscript{64}
Adrenal insufficiency is a condition that results in inadequate amounts of cortisol. Cortisol helps maintain normal blood pressure, cardiovascular function, and blood glucose (sugar) levels, especially during injury and illness.

Jane is at risk for adrenal crisis during illness (such as fever, diarrhea, vomiting), injury, and surgery. Jane MUST receive extra cortisol (glucocorticoid) during these times to avoid severe complications, including death.

This letter is not exhaustive and is not a substitute for contact with the Pediatric Endocrinology physician on call available 24 hours/day (phone ###). Please follow the instructions and contact us immediately.

**REGULAR HOME TREATMENT**

As part of her regular home treatment, Jane Doe-Smith receives cortisol replacement in the form of hydrocortisone tablets (5 mg / 10 mg). Her total daily hydrocortisone dose is ### mg. This is given as ### mg at ### am, ### mg at ### pm, and ### mg at ### pm.

**SICK DAY HOME TREATMENT**

For fever >38°C (100.4°F), diarrhea, vomiting, or severe injury, please triple her total daily dose divided into 4 doses (### mg every 6 hours) until symptoms have resolved. Please contact the on-call Pediatric Endocrinology physician (phone ###).

If Jane cannot tolerate oral hydrocortisone or is unconscious, please give an intramuscular injection of hydrocortisone sodium succinate (Solu-Cortef®) according to the table below. Next, contact the on-call Pediatric Endocrinology physician (phone ###) and go to the nearest emergency department.

**Intramuscular Hydrocortisone (Solu-Cortef®) Doses for Emergency Use**

<table>
<thead>
<tr>
<th>Age range (years)</th>
<th>Dose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 3</td>
<td>25</td>
</tr>
<tr>
<td>&gt;3- ≤12</td>
<td>50</td>
</tr>
<tr>
<td>≥12</td>
<td>100</td>
</tr>
</tbody>
</table>

**EMERGENCY ROOM INSTRUCTIONS**

Room Jane immediately, monitor vital signs closely, and start an IV. Administer IV hydrocortisone ### mg every 6 hours. If unable to place IV in 15 minutes, please give hydrocortisone dose IM. Administer IV D5 NS at 1½ to 2 times maintenance with appropriate electrolytes. Collect electrolytes and blood glucose.

Please contact the on-call Pediatric Endocrinology physician (phone ###) immediately for further instructions. If Jane does not respond to above intervention, more intensive management may be required, including transfer to tertiary care.

**ADDITIONAL INSTRUCTIONS FOR MAJOR and MINOR SURGERIES**

Please call the Pediatric Endocrinology physician (phone ###) immediately when a decision to go to surgery is made. General guidelines for emergency surgery are as follows.

**Major Surgery:** Hydrocortisone 100 mg/m²/dose (### mg) IV every 6 hours during the length of the procedure with the first dose being administered at the induction of anesthesia. For the 24 hours following the procedure, give 100 mg/m²/day (### mg IV every 6 hours). On the second day following the procedure, decrease hydrocortisone to 50 mg/m²/24 hour (### mg every 6 hours) and transition to oral hydrocortisone when possible. On the third day after the procedure, decrease to 25 mg/m²/24 hour (### mg of hydrocortisone every 6 hours). If stable after this, transition back to usual hydrocortisone dose. While on intravenous (IV) fluids, the patient should receive D5 NS at 1½ to 2 times maintenance. After surgery, IV fluids can be titrated to her oral intake as tolerated.

**Minor Surgery:** 50 mg/m²/dose (### mg) IM 1 hour prior to procedure or 50 mg/m²/dose (### mg) IV during the procedure. Depending on the length of fasting or duration of the procedure, IV fluids should be started at D5 NS at 1½ to 2 times maintenance.

Figure 1 Adrenal Insufficiency Emergency Care Letter.

**ED TREATMENT OF ADRENAL CRISIS**

Vague and non-specific symptoms of AI make the diagnosis of adrenal crisis easily overlooked in the ED triage process. Hypotension and hypoglycemia can develop suddenly in the ED,55 even after normal triage assessments. Providers must exercise a high index of suspicion for adrenal crisis in any child who is at risk of AI (table 1 and box 1). In cases of known AI the ED letter (figure 1, modified from ref 66) or Adrenal Insufficiency Action Plan should be given to triage personnel on arrival to the ED to speed the process.

The initial stress dose of hydrocortisone sodium succinate given by family, EMS, or in ED should be followed by 50–100 mg/m²/d divided into 4 doses given every 6 hours or given by continuous infusion.1,12,60 In the ED, intravenous
Figure 2  Adrenal Insufficiency Action Plan.

Figure 3  Adrenal Insufficiency Instructions for Emergency Room Staff. CBC, complete blood count; IV, intravenous.
dosing is preferred for the initial stress dose, however, if an intravenous catheter cannot be placed quickly, the initial dose should be given intramuscularly. Ongoing stress doses are typically given parenterally for the first 24–48 hours and then transitioned to oral dosing if feasible. Because hydrocortisone sodium succinate in high doses has mineralocorticoid effect, no fludrocortisone is needed while the patient receives intravenous fluids and stress doses of hydrocortisone.

Appropriate evaluation (as described above) should include biochemical documentation of the AI (serum cortisol and plasma ACTH levels), assessment of hydration and acid-base status, and investigation of an underlying precipitant. Ideally, a blood sample should be collected prior to administration of hydrocortisone sodium succinate, especially for patients with a suspected new diagnosis of AI; however, treatment should NOT be delayed if obtaining a blood sample proves difficult.

In an acute adrenal crisis, hypovolemia should be rapidly reversed with a 20 mL/kg bolus of isotonic solution, preferably normal saline. Hypoglycemia should be treated with a 2.5 mL/kg bolus of 10% dextrose solution and repeated if the response is not adequate.

CONCLUSIONS

Patients with AI (primary or secondary) may present to EMS personnel or the ED in an acute life-threatening crisis needing prompt and effective management to avoid severe consequences. This document offers evidence and consensus-based expert guidelines for most effective management of AI in the emergent scenario. A high index of suspicion needs to be maintained in all patients at risk for acute adrenal crisis.

Author affiliations
1 Department of Pediatrics, University of Minnesota Masonic Children’s Hospital, Minneapolis, Minnesota, USA
2 Department of Pediatrics, Nationwide Children’s Hospital, Columbus, Ohio, USA
3 Department of Pediatrics, Children’s Hospital of Los Angeles, Los Angeles, California, USA
4 Department of Pediatrics, MedStar Georgetown University Hospital, Washington, DC, USA
5 Department of Pediatrics, Le Bonheur Children’s Hospital, Memphis, Tennessee, USA
6 Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
7 Department of Pediatrics, UH Rainbow Babies and Children’s Hospital, Cleveland, Ohio, USA
8 Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada

Contributors All the authors have participated in the concept and design, analysis and interpretation of data, drafting or revising of the manuscript, have approved the manuscript as submitted, and have agreed to be accountable for all aspects of the work.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests BSM is a consultant for AbbVie, Ascendis, Ferring, Novo Nordisk, Pfizer, Sandoz, Soleno and Tolmar and has received research support from Alexion, Ascendis, BioMarin, Endo Pharmaceuticals, Genentech, Genzyme, Novo Nordisk, Opko, Sandoz, Sangamo, Shire, Tolmar and Versartis. MK received grant support from T1D Exchange Quality Improvement Collaborative. MG is a consultant for Spruce Biosciences, Millendo, Pfizer, and BridgeBio. KS receives research support from the DHHS Federal Food and Drug Administration, NIH National Cancer Institute, March of Dimes, National Science Foundation, Spruce Biosciences, Alexion and Neurocrine.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES


